Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.

CONCLUSION: The findings from this study suggest that 12 weeks' treatment of sofosbuvir plus daclatasvir and sofosbuvir plus ledipasvir was both efficacious and well tolerated treatment in Egyptian patients with HCV genotype 4 infection. PMID: 31573893 [PubMed - as supplied by publisher]
Source: Current Drug Safety - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Saf Source Type: research